These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36950134)

  • 21. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
    Tang Y; Zhang Y; Hu X
    Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study.
    Antwi SO; Craver EC; Nartey YA; Sartorius K; Patel T
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of signature trends across the spectrum of non-alcoholic fatty liver disease using deep learning method.
    Park I; Kim N; Lee S; Park K; Son MY; Cho HS; Kim DS
    Life Sci; 2023 Feb; 314():121195. PubMed ID: 36436619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
    Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
    J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
    Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
    Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
    Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
    Plaz Torres MC; Bodini G; Furnari M; Marabotto E; Zentilin P; Strazzabosco M; Giannini EG
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
    J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease.
    Frades I; Andreasson E; Mato JM; Alexandersson E; Matthiesen R; Martínez-Chantar ML
    PLoS One; 2015; 10(5):e0124544. PubMed ID: 25993042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma.
    Kurokawa S; Yoneda M; Ogawa Y; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A; Hotta K
    BMC Gastroenterol; 2022 Jun; 22(1):278. PubMed ID: 35655171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism.
    M Onorato A; Fiore E; Bayo J; Casali C; Fernandez-Tomé M; Rodríguez M; Domínguez L; Argemi J; Hidalgo F; Favre C; García M; Atorrasagasti C; Mazzolini GD
    Liver Int; 2021 Jul; 41(7):1677-1693. PubMed ID: 33641248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.